Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Faeth Therapeutics, Inc. (FTH)

Faeth Therapeutics Q3 net loss widens to $20.4 million from $4.6 million

Negative Impact 3 of 5 earnings Written later

Faeth Therapeutics reported a third-quarter 2026 net loss of $20.4 million, or $0.79 per share, compared with $4.6 million, or $3.62 per share, a year earlier, as research and development and general and administrative expenses rose sharply. Cash, cash equivalents and marketable securities reached $174.8 million at September 30, 2026, up from $21.2 million at December 31, 2025, and the company expects topline Phase 2 PIK-201 data by year-end 2026.

Key points

  • Net loss of $20.4 million ($0.79 per share) for the quarter ended September 30, 2026, versus $4.6 million ($3.62 per share) a year earlier
  • R&D expenses of $11.7 million, up from $2.5 million; G&A expenses of $10.4 million, up from $2.3 million
  • Cash, cash equivalents and marketable securities of $174.8 million at September 30, 2026, versus $21.2 million at December 31, 2025
  • Topline results from the Phase 2 PIK-201 trial in endometrial cancer are expected by year-end 2026

The filing

CompanyFaeth Therapeutics, Inc. (FTH)
Form8-K, current report
Filed with the SECNov 3, 2026, 8:14 AM ET
Accession number0001193125-26-444410

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.